vs

Side-by-side financial comparison of InMed Pharmaceuticals Inc. (INM) and Iveda Solutions, Inc. (IVDA). Click either name above to swap in a different company.

InMed Pharmaceuticals Inc. is the larger business by last-quarter revenue ($820.2K vs $626.0K, roughly 1.3× Iveda Solutions, Inc.). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -258.6%, a 11.3% gap on every dollar of revenue. On growth, InMed Pharmaceuticals Inc. posted the faster year-over-year revenue change (-26.2% vs -64.1%). Over the past eight quarters, Iveda Solutions, Inc.'s revenue compounded faster (34.4% CAGR vs -16.4%).

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

Iveda Solutions, Inc. is a technology provider specializing in cloud-based AI video surveillance, IoT-enabled smart sensing, and integrated smart city solutions. It serves public sector, enterprise, and education clients across North America and Asia, with core offerings covering remote security monitoring, smart facility management, and real-time data analysis tools for public safety use cases.

INM vs IVDA — Head-to-Head

Bigger by revenue
INM
INM
1.3× larger
INM
$820.2K
$626.0K
IVDA
Growing faster (revenue YoY)
INM
INM
+37.8% gap
INM
-26.2%
-64.1%
IVDA
Higher net margin
INM
INM
11.3% more per $
INM
-247.3%
-258.6%
IVDA
Faster 2-yr revenue CAGR
IVDA
IVDA
Annualised
IVDA
34.4%
-16.4%
INM

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
INM
INM
IVDA
IVDA
Revenue
$820.2K
$626.0K
Net Profit
$-2.0M
$-1.6M
Gross Margin
22.5%
3.6%
Operating Margin
-247.3%
-262.7%
Net Margin
-247.3%
-258.6%
Revenue YoY
-26.2%
-64.1%
Net Profit YoY
21.2%
-7.1%
EPS (diluted)
$-0.51
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INM
INM
IVDA
IVDA
Q4 25
$820.2K
$626.0K
Q3 25
$1.1M
$1.7M
Q2 25
$1.3M
$1.5M
Q1 25
$1.3M
$1.5M
Q4 24
$1.1M
$1.7M
Q3 24
$1.3M
$2.4M
Q2 24
$1.3M
$1.5M
Q1 24
$1.2M
$346.8K
Net Profit
INM
INM
IVDA
IVDA
Q4 25
$-2.0M
$-1.6M
Q3 25
$-1.7M
$-221.3K
Q2 25
$-1.8M
$-564.2K
Q1 25
$-2.1M
$-793.7K
Q4 24
$-2.6M
$-1.5M
Q3 24
$-1.7M
$-581.4K
Q2 24
$-1.9M
$-599.0K
Q1 24
$-1.7M
$-1.3M
Gross Margin
INM
INM
IVDA
IVDA
Q4 25
22.5%
3.6%
Q3 25
36.0%
31.3%
Q2 25
44.2%
29.1%
Q1 25
13.9%
19.5%
Q4 24
41.5%
11.9%
Q3 24
39.0%
17.1%
Q2 24
36.3%
32.7%
Q1 24
24.7%
52.5%
Operating Margin
INM
INM
IVDA
IVDA
Q4 25
-247.3%
-262.7%
Q3 25
-154.2%
-13.0%
Q2 25
-137.1%
-34.8%
Q1 25
-168.1%
-56.7%
Q4 24
-231.6%
-87.3%
Q3 24
-132.7%
-25.4%
Q2 24
-150.5%
-39.7%
Q1 24
-146.9%
-384.1%
Net Margin
INM
INM
IVDA
IVDA
Q4 25
-247.3%
-258.6%
Q3 25
-154.2%
-13.4%
Q2 25
-137.1%
-36.9%
Q1 25
-168.1%
-53.8%
Q4 24
-231.6%
-86.7%
Q3 24
-132.7%
-24.2%
Q2 24
-151.0%
-39.0%
Q1 24
-146.9%
-371.9%
EPS (diluted)
INM
INM
IVDA
IVDA
Q4 25
$-0.51
$-0.33
Q3 25
$-0.44
$-0.07
Q2 25
$-0.07
$-0.20
Q1 25
$-1.94
$-0.28
Q4 24
$-3.64
$-0.60
Q3 24
$-2.71
$-0.27
Q2 24
$2.39
$-0.30
Q1 24
$-3.58
$-0.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INM
INM
IVDA
IVDA
Cash + ST InvestmentsLiquidity on hand
$7.0M
$5.2M
Total DebtLower is stronger
$393.4K
Stockholders' EquityBook value
$9.6M
$4.8M
Total Assets
$11.2M
$6.4M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INM
INM
IVDA
IVDA
Q4 25
$7.0M
$5.2M
Q3 25
$9.4M
$3.3M
Q2 25
$11.1M
$1.6M
Q1 25
$4.7M
$2.5M
Q4 24
$3.5M
$2.6M
Q3 24
$5.6M
$3.6M
Q2 24
$6.6M
$2.9M
Q1 24
$3.9M
Total Debt
INM
INM
IVDA
IVDA
Q4 25
$393.4K
Q3 25
$306.4K
Q2 25
$365.3K
Q1 25
$340.8K
Q4 24
$376.2K
Q3 24
$545.9K
Q2 24
$564.0K
Q1 24
$480.0K
Stockholders' Equity
INM
INM
IVDA
IVDA
Q4 25
$9.6M
$4.8M
Q3 25
$11.6M
$3.8M
Q2 25
$13.4M
$1.5M
Q1 25
$7.0M
$1.7M
Q4 24
$6.2M
$2.5M
Q3 24
$8.4M
$4.1M
Q2 24
$9.2M
$2.8M
Q1 24
$11.1M
$3.3M
Total Assets
INM
INM
IVDA
IVDA
Q4 25
$11.2M
$6.4M
Q3 25
$13.4M
$5.8M
Q2 25
$15.6M
$4.4M
Q1 25
$9.3M
$4.5M
Q4 24
$8.5M
$5.2M
Q3 24
$10.5M
$9.1M
Q2 24
$11.8M
$6.8M
Q1 24
$6.6M
Debt / Equity
INM
INM
IVDA
IVDA
Q4 25
0.08×
Q3 25
0.08×
Q2 25
0.25×
Q1 25
0.20×
Q4 24
0.15×
Q3 24
0.13×
Q2 24
0.20×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INM
INM
IVDA
IVDA
Operating Cash FlowLast quarter
$-2.4M
$-252.4K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INM
INM
IVDA
IVDA
Q4 25
$-2.4M
$-252.4K
Q3 25
$-1.6M
$-317.0K
Q2 25
$-1.8M
$-1.3M
Q1 25
$-1.7M
$-126.0K
Q4 24
$-2.5M
$-889.8K
Q3 24
$-1.8M
$-1.2M
Q2 24
$-1.0M
$-999.7K
Q1 24
$-1.9M
$-1.3M
Free Cash Flow
INM
INM
IVDA
IVDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-889.8K
Q3 24
$-1.5M
Q2 24
$-1.1M
Q1 24
$-1.9M
$-1.5M
FCF Margin
INM
INM
IVDA
IVDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-51.1%
Q3 24
-64.1%
Q2 24
-72.6%
Q1 24
-165.0%
-427.3%
Capex Intensity
INM
INM
IVDA
IVDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.0%
Q3 24
12.5%
Q2 24
7.5%
Q1 24
0.0%
54.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons